DUBLIN, Oct. 20, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/cn59hb/2016_emerging) has announced the addition of the "2016 Emerging Opportunities in the US Hospital Infectious Disease Testing Market" report to their offering.
This new report contains 997 pages, 87 tables, and presents a comprehensive analysis of the US hospital infectious disease testing market, including:
- Major issues pertaining to the US hospital laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next five years
- Current scientific views on definition, epidemiology, and etiology of major infectious diseases and microorganisms
- Volume and sales forecasts for 80 infectious disease tests performed in US hospital laboratories
- Instrumentation technologies and feature comparison of leading analyzers
- Sales and market shares of leading suppliers by test
- Emerging diagnostic technologies and their potential market applications
- Product development opportunities
- Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies
- Business opportunities and strategic recommendations for suppliers
Companies Mentioned
- Abbott
- Affymetrix
- Beckman Coulter/Danaher
- Becton Dickinson
- bioMerieux
- Bio-Rad
- Cepheid
- Diamedix
- DiaSorin
- Eiken Chemical
- Elitech Group
- Enzo Biochem
- Fujirebio
- Grifols
- Hologic/Gen-Probe
- ID Biomedical/GSK
- Kreatech/Leica
- Lonza
- Ortho-Clinical Diagnostics
- Qiagen
- Roche
- Scienion
- Sequenom
- SeraCare
- Siemens
- Takara Bio
- Thermo Fisher/Life Technology
- Wallac/PE
- Wako
For more information visit http://www.researchandmarkets.com/research/cn59hb/2016_emerging
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
